At Alchemab Therapeutics the first step in the drug discovery journey starts not in a laboratory but with an individual person – not a scientist or researcher, but a patient. The biotech aims to target diseases across neurology and oncology through naturally occurring protective antibodies, mining the antibody receptors of individuals who are especially resistant to or have even recovered from serious illness to develop therapeutic products.
“Alchemab was founded on the idea that there are people who are resilient to disease, or perhaps just unusually well,...
